ULTRAGENYX PHARMACEUTICAL INC. Preferred Stock, Accretion of Redemption Discount
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Preferred Stock, Accretion of Redemption Discount of $4.43 million for the 12-month period ending 2014-12-31, per its 10-K filed 2016-02-26.
Discontinued › Shareholders' Equity
us-gaap:PreferredStockAccretionOfRedemptionDiscount · last filed 2016-02-26
- ULTRAGENYX PHARMACEUTICAL INC. preferred stock, accretion of redemption discount for fiscal 2014 was $4.43M, a 67.29% decline from fiscal 2013.
- ULTRAGENYX PHARMACEUTICAL INC. preferred stock, accretion of redemption discount for fiscal 2013 was $13.54M, a 694.78% increase from fiscal 2012.
- ULTRAGENYX PHARMACEUTICAL INC. preferred stock, accretion of redemption discount for fiscal 2012 was $1.70M.
| Period end | Preferred Stock, Accretion of Redemption Discount 12 month |
|---|---|
| 2014-12-31 | $4.43M 10-K · filed 2016-02-26 |
| 2013-12-31 | $13.54M 10-K · filed 2016-02-26 |
| 2012-12-31 | $1.70M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |